Focus this week: sorting out the core product sales of overseas pharmaceutical enterprises in 2021
This week, we focused on 18 overseas leading pharmaceutical enterprises and conducted an extensive and in-depth combing of their product performance on sale in 2021. From the field of disease and target, we take a comprehensive inventory of product layout and market performance of overseas pharmaceutical companies, including 10 diseases and over 400 drug categories, focusing on anti tumor, self immunity, anti infection, diabetes, nerve, respiration, ophthalmology, vaccines, rare diseases, and COVID-19 related products. The product pattern of multinational pharmaceutical enterprises will guide the development of China’s pharmaceutical industry. According to the financial report data of multinational pharmaceutical enterprises in 2021, we find that:
In terms of market structure,
In covid-19 products, the amount of vaccine is rapid, and Pfizer vaccine and antiviral small molecules work together to become the biggest winner;
The ranking of cancer drugs is almost unchanged, and the share composition is relatively stable. Gilead and GSK grow rapidly, but the volume is still small;
Many heavy varieties in the field of self exemption are facing the patent cliff, and Alberto has arranged new products to defend its leading position;
Anti infection, diabetes, and respiratory drugs were highly concentrated in brands, which were controlled by Gillie, Novo Nord and GSK respectively. The concentration of ophthalmic drugs is high, with eylea monopolizing more than 70%.
In terms of sector development,
Cancer drugs are still the hottest sub field, accounting for 26% of revenue; The growth rate of heavy products slowed down due to the impact of biological analogues, with a year-on-year increase of 7.9%;
There are many heavy varieties of autoimmune products, and their weight is second only to tumor drugs and covid-19 products. They have developed rapidly, with a growth rate of 11.5% (the third in sub fields);
The use of drugs for rare diseases increased rapidly (+ 17.7%), ranking first in the sub field.
In the performance of China, AstraZeneca topped the performance of multinational pharmaceutical enterprises in China with a revenue of US $6.011 billion, and accounted for the highest proportion of the company’s overall revenue (16%); With a year-on-year growth rate of 60%, Merck became the fastest growing multinational pharmaceutical enterprise in the Chinese market in 2021, with a revenue of US $4.262 billion, ranking second.
From the perspective of branches, Pfizer officially topped the list of pharmaceutical business revenue. Covid-19 vaccine contributed 46.2% of the revenue of the pharmaceutical sector, driving the overall revenue growth of the pharmaceutical sector as high as 95%; The only commercial product of spik mode, with a revenue of 176.5 billion US dollars; Bojian’s performance decreased significantly (- 17%) due to the sharp decline in the sales of its flagship product Tysabri (- 49%) and the controversial new Alzheimer’s disease treatment drug aduhelm.
In terms of products, Pfizer mRNA covid-19 vaccine sales reached US $36.781 billion, becoming the largest product in 2021; Humira remained the “king of medicine” of vaccine products, and its revenue exceeded US $20 billion for the first time; Among the top 30 varieties in sales, small molecules account for 30%, and Revlimid has become the best-selling small molecule drug with us $12.821 billion. In addition to covid-19 related varieties, the revenue of Merck star product keytruda increased by US $2.806 billion year-on-year, becoming the single product with the largest increase in absolute sales, and is expected to succeed Humira as the new king of biological drugs.
Market review of innovative medicine stocks in the pharmaceutical sector:
Staidson(Beijing) Biopharmaceuticals Co.Ltd(300204) , Frontier Biotechnologies Inc(688221) -u, Jenkem Technology Co.Ltd(688356) , Shanghai Junshi Biosciences Co.Ltd(688180) -u, Guangdong Zhongsheng Pharmaceutical Co.Ltd(002317) . The last five are Huadong Medicine Co.Ltd(000963) , Shenzhen Chipscreen Biosciences Co.Ltd(688321) , Shanghai Allist Pharmaceuticals Co.Ltd(688578) -u, Yifan Pharmaceutical Co.Ltd(002019) , Jiangsu Jibeier Pharmaceutical Co.Ltd(688566) .
The top 5 gainers and losers in the pharmaceutical innovative drugs sector of Hong Kong stocks this week are jiakesi-b, Shanghai Junshi Biosciences Co.Ltd(688180) , Baiji Shenzhou, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.Ltd(688505) , LVYE pharmaceutical. The last five are Geli pharmaceutical-b, tengshengbo pharmaceutical-b, Jiahe biology-b, Yunding xinyao-b and kangfang biology-b.
IPO this week: Heyuan Biology – the first share of cdmo in gene therapy of Kechuang board
Risk tips: 1) negative policies continue to exceed expectations; 2) The growth rate of the industry was lower than expected.
